Nitrosigine as Effective as Higher Dose of Citrulline Malate for Vasodilation, Says New Study
NEWS From Nutritional Outlook: At the 2019 ISSN (International Society of Sports Nutrition) Annual Conference, researchers from the University of Arkansas presented the results of an independent study showing the impact of the patented Nitrosigine (from Nutrition21; Purchase, NY) on blood flow. Entitled “The Acute Effects of Citrulline Malate and Bonded Arginine Silicate Supplementation on Vasodilation of Young Adults,” results were presented by lead author Jeffrey Rogers. Nutrition 21 provided no support and did not participate in the design or implementation of the study.
Nitrosigine®, Velositol®, nooLVL®, Chromax®, Lepidamax®, Zinmax®, and their associated logos are registered trademarks of Nutrition21, LLC. All third party trademarks are the property of their respective owners. Nutrition21, LLC's products are protected by a number of patents including, but not limited to: US Patent Nos. 6,809,115; 6,803,456; 7,576,132; 8,062,677; 8,933,022; 9,005,637; 9,028,879; 9,119,835; 9,421,170; 9,597,404; 9,675,702; 10,183,049; 10,245,325; and 10,363,222.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.